← Back to Search

ABBV-154 Dose A for ABBV-154 Syndrome

Phase 1
Waitlist Available
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
- Body Mass Index (BMI) is ≥ 18.0 to ≤ 29.9 kg/m2 after rounding to the nearest tenth at screening and upon initial confinement.
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up approximately up to 72 days
Awards & highlights

Study Summary

This trial will assess the safety and movement of ABBV-154 through the body in adult healthy volunteers.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~approximately up to 72 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately up to 72 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Apparent Terminal Phase Elimination Rate Constant (β)
Maximum Observed Plasma Concentration (Cmax)
Number of Participants with Adverse Events
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: ABBV-154 Dose BExperimental Treatment1 Intervention
Participants will receive subcutaneous dose of ABBV-154 Dose Formulation B.
Group II: ABBV-154 Dose AExperimental Treatment1 Intervention
Participants will receive subcutaneous dose of ABBV-154 Dose Formulation A.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ABBV-154 Dose Formulation A
2022
Completed Phase 1
~40
ABBV-154 Dose Formulation B
2022
Completed Phase 1
~40

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

AbbVieLead Sponsor
954 Previous Clinical Trials
501,065 Total Patients Enrolled
ABBVIE INC.Study DirectorAbbVie
394 Previous Clinical Trials
145,899 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are contributing to the study's data?

"Affirmative, according to clinicaltrials.gov this investigation is currently accepting applications. Originally posted on October 18th 2022 and revised as recently as the 25th of that month, it requires forty participants from two distinct sites."

Answered by AI

Are individuals aged 40 or younger being enrolled in the present investigation?

"Applicants must be between the age of majority and 60 years old to quality for this clinical trial."

Answered by AI

Has ABBV-154 Dose B received governmental sanctioning?

"There is limited clinical evidence concerning ABBV-154 Dose B's safety, so we rated it a 1 on our scale."

Answered by AI

What qualifications are necessary for a participant to be eligible for this experiment?

"This clinical trial requires a cohort of 40 individuals between ages 18 and 60 to evaluate the efficacy of abbv-154. The main condition for enrolment is that applicants must have Body Mass Index (BMI) scores from 18.0 kg/m2 up to 29.9 kg/m2 after rounding at both screening and initial confinement stages."

Answered by AI

Are there any remaining vacancies left for participants in this experiment?

"Affirmative, clinicaltrials.gov data reveals that this medical investigation is still actively recruiting patients. Originally posted on October 18th 2022 and last updated on the 25th of the same month, 40 subjects need to be admitted at two different research sites."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants
2022. "Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05556226.
~16 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top